Silicon Valley’s timeline for "solving" human health is dangerously optimistic, but AI is quietly breaking pharma’s biggest ...
US pharmaceutical giant Eli Lilly inked a $2.75 billion deal with a Hong Kong-listed biotech firm to create new medicines ...
Drug discovery has long been defined by time, cost, and repeated failure. Medvolt AI is using OpenAI-enabled intelligence to ...
A high burden of infectious diseases coexists with a rapid rise in non-communicable diseases such as diabetes, cancer, and ...
The U.S. will impose a 100% tariff on drug imports with some exceptions. Takeda plans to cut 634 jobs in the U.S. as part of ...
Chair, President, and CEO Sheila DeWitt, PhD, shares reflections and outlook on 15 Years of Drug Discovery and Four Landmark M&A Transactions BOSTON, March 31, 2026 /PRNewswire/ -- In honor of Women's ...
Phase 1b norovirus challenge study is underway at Emory University School of MedicineCDI-988 is the first oral antiviral ...
The PREVAiLS study, believed to be the only recruiting phase 3 ALS trial, aims to slow disease progression and preserve ...
One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...
The deal grants Lilly exclusive global rights to use Insilico's Pharma.AI platform for drug discovery and development across ...
The Type C Meeting is part of a multidisciplinary strategy to seek alignment with the FDA on readiness to initiate a Phase 3 pivotal trial in MSA. Alterity received written feedback supporting its ...
The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results